At Panacea we believe in a better way of doing things. Everyone talks about delivering a fresh, dynamic, approach – but at Panacea you will find that we deliver on this promise. Our highly experienced team enjoy working with clients to find the best way to safeguard their investment and reputation, and we take pride in providing the best possible vigilance and regulatory affairs services to the pharmaceutical industry. Currently, Panacea are responsible for Marketing Authorisation’s in every EU country and have an international reputation which is respected by regulators.
We are flexible and responsive, whether it’s a one-off task, a fixed term project (large or small) or a continuous relationship over several years. We know that each client is different; each has a specific budget, timescale, and objective, and we do everything we can to work with them to ensure that budget targets are met, timescales respected, and objectives achieved. Individually, everyone at Panacea takes personal responsibility for providing the highest quality of work. Collectively, we offer a responsive, cost effective, flexible, and professional service.
The field of post-marketing pharmacovigilance is very different in Europe, largely due to the legislation, and we had the option of bringing someone into the business to set-up our own internal post-marketing service, or working together with a company who could provide pharmacovigilance support in the post-marketing phase. We decided to go with Panacea Pharma Projects because we felt that they really understood our needs and requirements.
We’ve been very impressed by the way PPP took such a structured approach to reviewing the requirements of the new pharmacovigilance legislation, and to implementing them on our behalf in such a professional and timely way.
The wealth of experience and expertise in PPP’s team provides us with reassurance that we are in good hands.
Panacea has provided training to our safety and pharmacovigilance department on the new pharmacovigilance legislation that came into effect in 2012, and how it will affect our daily safety activities. This is typical of the willingness and ability of Panacea to offer a bespoke service that is tailored to our unique business needs.
Our link with Panacea has allowed us to bid on projects that previously we would have had to decline. Each proposal is different in terms of the scope of services required, but throughout all of them Panacea has provided us with excellent post-marketing pharmacovigilance support.